Cargando…

Antiviral therapy leads to histological improvement in HBeAg-negative chronic hepatitis B patients

Detalles Bibliográficos
Autores principales:	Basyigit, Sebahat, Sapmaz, Ferdane, Yeniova, Abdullah O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585405/ https://www.ncbi.nlm.nih.gov/pubmed/26423225

Ejemplares similares

Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients
por: Papachrysos, Nikolaos, et al.
Publicado: (2015)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Prevalent HBeAg-negative HBV DNA-positive Chronic Hepatitis B Individuals in Bangladesh
por: Rashed Ul Islam, SM, et al.
Publicado: (2021)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients
por: Esmaeelzadeh, Abbas, et al.
Publicado: (2017)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study
por: Yang, Xiaoling, et al.
Publicado: (2017)

Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients
por: Loureiro, Dimitri, et al.
Publicado: (2019)

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection
por: Kadelka, Sarah, et al.
Publicado: (2021)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013)

Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2018)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients
por: Ahmed, Fatima A., et al.
Publicado: (2019)

Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis
por: Zheng, Rui-dan, et al.
Publicado: (2010)

qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels
por: Gan, Qinyi, et al.
Publicado: (2022)

The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis
por: Hao, Zhang, et al.
Publicado: (2018)

Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China
por: Li, Runqin, et al.
Publicado: (2021)

IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2013)

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml
por: Wu, Yingping, et al.
Publicado: (2021)

Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD
por: Sapmaz, Ferdane, et al.
Publicado: (2016)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
por: Roade, Luisa, et al.
Publicado: (2023)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
por: Kosinska, Anna D., et al.
Publicado: (2021)

Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study
por: Wei, Sufang, et al.
Publicado: (2022)

The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
por: Kramvis, Anna
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e12ujs42ehjg2ms9jd6hjkmi58